Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (T2DM) treated with stable dose of metformin \> or = to 1500mg/day as monotherapy for at least 8 weeks~* Hemoglobin A1c (HbA1c) 7% to 10% at screening~* Body mass index (BMI) \< or = to 45 kg/m2~Exclusion Criteria:~* History of taking antihyperglycemic therapy other than metformin or metformin extended release (XR) during the 8 weeks prior to screening~* History of taking a dipeptidyl peptidase-4 (DPP-4) inhibitor or pramlintide during 12 weeks prior to screening~* History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study~* History of prescription or over the counter weight loss medication during 3 months prior to screening~* Previous exposure to exenatide or any glucagon-like peptide-1 (GLP-1) receptor agonist during 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bydureon (Type: EXPERIMENTAL): Once weekly injected exenatide
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).